Patients who received an intracanalicular dexamethasone insert after cataract surgery experienced early, sustained relief of pain and inflammation, according to a study.
Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix), which was FDA approved in December 2018, is indicated for the treatment of ocular pain after ophthalmic surgery and lasts up to 30 days with one treatment.
The insert offers consistent and tapered drug dosing after cataract surgery, study co-author Sydney L. Tyson, MD, MPH, told Ocular Surgery News.
“Dextenza eliminates patient compliance concerns with
Uncategorized